Business Wire

NE-DESIGN-DATA

23.5.2017 14:02:47 CEST | Business Wire | Press release

Share
Design Data's SDS/2 2016 Earns SCI Assessed Status

Design Data, a leader in 3D steel detailing and Building Information Modeling (BIM) software, announced that the Steel Construction Institute (SCI) has recently assessed Design Data’s SDS/2 2016 software for connection design.

SDS/2 takes a uniquely intelligent approach in its connection design by considering framing conditions and erectability, automatically performing clash prevention as a part of its connection design. In addition, SDS/2 can value engineer the connections on a project, helping users to design the most economical connections to fabricate and erect.

SCI’s process involved reviewing connection design output in depth for each connection type: partial depth end plates, fin plates, column splices, beam splices, bracing connections, and bolted moment connections (end plates). Each connection was reviewed in detail for numerical correctness for the specific arrangement, but also to demonstrate that important principles common to all connections were correctly implemented.

SCI’s assessment was made in accordance with Eurocode 3: Design of steel structures, BS EN 1993, and the relevant UK National Annexes. Additionally, the “Green Books” were used as reference documents, being referenced in the U.K. National Annex and the de facto standard in the U.K.

“Achieving SCI Assessed status is a key advantage for us entering the U.K. and European markets,” said Damon Scaggs, president of Design Data. “With incorporating European design codes for the first time into SDS/2 — which already implements American, Canadian and Australian design codes — it was important to subject the software to the rigorous and extensive testing SCI conducted. This will help give our new European customers the confidence in our connections that our customers around the world have had for more than 30 years.”

According to the SCI Assessed website, “SCI Assessed” is an established quality mark that is awarded to testify that manufacturers' technical data has been independently verified by SCI. The scheme provides reliability for the range of performance data offered by suppliers particularly where, for example, the product is new or the values are based on calculation methods outside the scope of established standards.

About Design Data

Design Data, a Nemetschek company, is a leading software innovator for the steel industry's fabrication, detailing and engineering sectors. SDS/2 software products provide automatic connection optimization, detailing, engineering information, fabrication data and much more, reducing the time required to design, detail, fabricate and erect steel. Founded in 1981 and headquartered in Lincoln, Nebraska, USA, the company serves customers in 17 countries. Information on Design Data and SDS/2 can be found at: www.sds2.com .

About SCI

SCI has been a trusted, independent source of information and engineering expertise globally for over 30 years, and remains the leading, independent provider of technical expertise and disseminator of best practice to the steel construction sector. SCI offers comprehensive advice, technical information, consultancy services and membership for manufacturers, engineers and designers for every aspect of steel construction.

Contact:

Design Data
Damon Scaggs, 402-441-4000
President
Fax: 402-441-4045
damon@sds2.com
www.sds2.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye